EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Open Access

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C

Rona Yaeger, Jared Weiss, Meredith S Pelster, Alexander I Spira, Minal Barve, Sai-Hong I Ou, Ticiana A Leal, Tanios S Bekaii-Saab, Cloud P Paweletz, Grace A Heavey, James G Christensen, Karen Velastegui und 3 weitere

New England Journal of Medicine · 05.01.2023 · 388 (1) · 44-54

DOI: 10.1056/nejmoa2212419 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 05.01.2023. Verfasst von Rona Yaeger und 14 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (R.Y.); Lineberger Comprehensive Cancer Center, University of North…. Hauptthemen laut MEDLINE: Cetuximab, Colorectal Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 537-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Memorial Sloan Kettering Cancer Center, Mirati Therapeutics, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CetuximabColorectal NeoplasmsAntineoplastic AgentsHumansAntineoplastic Combined Chemotherapy ProtocolsPiperazinesProto-Oncogene Proteins p21(ras)AcetonitrilesPyrimidines

Substanzen

CetuximabPiperazinesProto-Oncogene Proteins p21(ras)Antineoplastic AgentsadagrasibAcetonitrilesPyrimidinesKRAS protein, human

Autor:innen und Institutionen

  • From the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (R.Y.); Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill (J.W.); Sarah Cannon Research In…

ORCID-Profile: Samuel J Klempner

Förderung

  • NCI NIH HHS
  • Memorial Sloan Kettering Cancer Center
  • Mirati Therapeutics, Inc.

Zitieren

APA

Yaeger, R., Weiss, J., Pelster, M. S., Spira, A. I., Barve, M., Ou, S. I., Leal, T. A., Bekaii-Saab, T. S., Paweletz, C. P., Heavey, G. A., Christensen, J. G., Velastegui, K., Kheoh, T., Der-Torossian, H., & Klempner, S. J. (2023). Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. New England Journal of Medicine, 388(1), 44-54. https://doi.org/10.1056/nejmoa2212419

Vancouver

Yaeger R, Weiss J, Pelster MS, Spira AI, Barve M, Ou SI, et al. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. New England Journal of Medicine. 2023;388(1):44-54. doi:10.1056/nejmoa2212419

BibTeX
@article{Yaeger2023,
  author = {Yaeger, Rona and Weiss, Jared and Pelster, Meredith S and Spira, Alexander I and Barve, Minal and Ou, Sai-Hong I and Leal, Ticiana A and Bekaii-Saab, Tanios S and Paweletz, Cloud P and Heavey, Grace A and Christensen, James G and Velastegui, Karen and Kheoh, Thian and Der-Torossian, Hirak and Klempner, Samuel J},
  title = {Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {388},
  number = {1},
  pages = {44--54},
  doi = {10.1056/nejmoa2212419}
}
Kostenlos starten →